Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer

Japanese Journal of Clinical Oncology

Volumn 32, Issue 12, 2002, Pages 536-542

  Ou, Yen Chuan ^a,b   Chen, Jung Ta ^b,c   Yang, Chi Rei ^a,b   Cheng, Chen Li ^a   Ho, Hao Chung ^a   Ko, Jiunn Liang ^b   Hsieh, Yih Shou ^b  

^a Division of Urology   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Adenocarcinoma; Prostate; PSA failure; Stage T1c

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CLINICAL ASSESSMENT; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE EVALUATION; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; TAIWAN; TREATMENT FAILURE; BIOPSY; BLOOD; FORECASTING; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; SURVIVAL RATE;

BIOPSY; FORECASTING; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036988669     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyf110     Document Type: Article

References (22)

1. Brawer MK. Prostate-specific antigen. Current status. CA Cancer J Clin 1999;49:264-81.
2. Pound CR, Walsh PC, Epstein JI, Chan DW, Partin AW. Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World J Urol 1997;15:373-7.
3. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996; 155:816-20.
4. Boring CC, Squires TS, Tong T. Cancer statistics, 1992. Cancer 1992;42: 19-39.
5. Yang CR, Ou YC, Ho HC, Kao YL, Cheng CL, Chen JT, et al. Unsuspected prostate carcinoma and prostatic intraepithelial neoplasm in Taiwanese patients undergoing cystoprostatectomy. Mol Urol 1999;3:33-9.
6. Yatani R, Shiraishi T, Nakakuki K, Kusano I, Takanari H, Hayashi T, et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst 1988;80:683-7.
7. Kabalin JN, Mcneal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of prostate in patients undergoing cystoprostatectomy for other cause: Incidence, histology and morphometric observations. J Urol 1988;141:1091-4.
8. Ogawa O, Egawa S, Arai Y, Tobisu KI, Yoshida O, Kato T. Preoperative predictors for organ-confined disease in Japanese patients with stage T1c prostate cancer. Int J Urol 1998;5:454-8.
9. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. Urol Clin N Am 1993;20:713-25.
10. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12.
11. Arnauld V, John EM, Fuad SF, Stamey TA. Multiple cancers in the prostate. Morphological features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-8.
12. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1c adenocarcinoma of prostate. J Urol 1997;157:2206-9.
13. Epstein JI, Pizov G, Walsh PC. Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer 1993;71: 3582-93.
14. Epstein JI, Walsh PC, Carmichael MJ, Brendler CB. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J Am Med Assoc 1994;270:368-74.
15. Lerner SE, Seay TM, Bluye ML, Bergstralh EJ, Barrett D, Zincke H. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol 1996;155:821-6.
16. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology 1997;49:887-93.
17. Olumi AF, Richie JP, Schultz DJ, D'Amico AV. Calculated volume of prostate cancer identifies patients with clinical stage T1c disease at high risk of biochemical recurrence after radical prostatectomy: A preliminary study. Urology 2000;56:273-7.
18. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis for an adjuvant therapy trial. J Clin Oncol 1997;15:1465-9.
19. Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failure after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997;37:1043-52.
20. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996;156:137-43.
21. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinoma of the prostate with 5 years of followup. J Urol 1993;149:1478-81.
22. Zentner PG, Pao LK, Benson MC, McMahon DJ, Schiff PB. Prostate-specific antigen density: A new prognostic indicator for prostate cancer. Int J Radiat Oncol Biol Phys 1993;27:47-55.